about
Profiling of Flavonol Derivatives for the Development of Antitrypanosomatidic DrugsHPLC assay for determination of amphotericin B in biological samples.Methoxylated 2'-hydroxychalcones as antiparasitic hit compounds.New amphotericin B-gamma cyclodextrin formulation for topical use with synergistic activity against diverse fungal species and Leishmania spp.Treatment of experimental visceral leishmaniasis with amphotericin B in stable albumin microspheres.In vitro effect of new formulations of amphotericin B on amastigote and promastigote forms of Leishmania infantum.Agitation Rate and Time for Complete Dissolution in BCS Biowaivers Based on Investigation of a BCS Biowaiver for Dexketoprofen Tablets.Real-time reverse transcription-PCR quantification of cytokine mRNA expression in golden Syrian hamster infected with Leishmania infantum and treated with a new amphotericin B formulation.Rationale and conditions for the requirement of chiral bioanalytical methods in bioequivalence studies.Efficacy of a new formulation of amphotericin B in murine disseminated infections by Candida glabrata or Candida tropicalis.Bioavailability and efficacy characteristics of two different oral liquid formulations of albendazole.Ex vivo anthelmintic activity of albendazole-sulphoxide enantiomers.Anti-leishmanial activity of a new formulation of amphotericin B.Egg albumin microspheres containing paracetamol for oral administration. I. In vitro characterization.Efficacy of alternative dosing regimens of poly-aggregated amphotericin B.An eutomer/distomer ratio near unity does not justify non-enantiospecific assay methods in bioequivalence studies.Efficacy of a new formulation of amphotericin B in a murine model of disseminated infection by Candida glabrata.Hemolytic and pharmacokinetic studies of liposomal and particulate amphotericin B formulations.Efficacy of low doses of amphotericin B plus allicin against experimental visceral leishmaniasis.Therapeutic actions of insulin-like growth factor I on APP/PS2 mice with severe brain amyloidosis.A multivariate investigation into the relationship between pharmaceutical characteristics and patient preferences of bioequivalent ibuprofen tabletsA novel formulation of solubilised amphotericin B designed for ophthalmic useEffect of PLGA hydrophilia on the drug release and the hypoglucemic activity of different insulin-loaded PLGA microspheresPermeability Characteristics of a New Antifungal Topical Amphotericin B Formulation with γ-CyclodextrinsTuning the Transdermal Delivery of Hydroquinone upon Formulation with Novel Permeation Enhancers.Egg albumin microspheres containing paracetamol for oral administration. II. In vivo investigationPreparation and characterization of albendazole beta-cyclodextrin complexesInvestigation on the possibility of biowaivers for ibuprofenEnantiomerical pharmacokinetic prevalence of (+) albendazole sulphoxide in Trichinella spiralis muscle larvaeA novel performing PEG-cholane nanoformulation for Amphotericin B deliveryEvaluating the Potential of Ursolic Acid as Bioproduct for Cutaneous and Visceral LeishmaniasisEffect of enantiomerism on the bioequivalence of a new ibuprofen 600-mg tablet formulation obtained by roller compactionAntifungal and Antiparasitic Drug DeliveryStereoselective drug release from ketoprofen and ricobendazole matrix tablets
P50
Q27719080-86B9A9EA-4991-41D8-BDBB-5494E02CB693Q33308557-9933CC2A-4BC3-4605-9C77-07144ABD9F6BQ36243812-F7DEE520-2CA8-496B-9003-7B56537D0DB9Q38977703-A823FA25-1AD1-473B-9238-FB53E96A8DC9Q39954346-A6A6CF40-6F9E-4AEF-8388-E37741B05595Q40106955-87E2F70E-D5CF-48E5-A98D-49CFC7CDD57AQ40665911-2EF11A0A-9559-48E3-86AA-EF8D28103218Q42112456-F3FBD79C-4D2C-4877-8A2A-0BB2449863E5Q43145405-C63CFFCB-33B8-4BC5-A983-FB780D72A3A7Q43280544-0DF04CAF-5198-4EC7-9F58-A3961708201FQ44277713-9C1536E4-F3A3-4C52-AC15-9D5DA6AC38ABQ44912040-EB171877-7880-4FC4-BEB0-BBB74A626DAEQ45011384-DD742DAE-2F7D-4906-B6CC-3D9711FB84FEQ45194539-4B1F0092-297C-43CD-8B05-2E7FBD1F0533Q46555681-CD094AB2-30D0-4E49-BAEF-CEC98C168F01Q46653297-2FD791EE-1087-40CC-B3BE-1BC5E7340348Q46767852-9B82A1D1-F304-47CF-8A5E-4DEEAF05B410Q48032209-4A3F4226-3993-4D8E-AF90-467E020188DCQ51747317-0CB8E1A7-9292-4F51-8FBB-071B93ABA481Q52038530-4393B73D-11DD-4B38-A400-FC72F44DA2F3Q57069441-2CCA9EC7-A1D0-43DC-9555-9A81CC23D531Q57617490-FBDC96E9-6DD2-45DA-AB1A-992FE51E84A6Q60357730-9C0957B0-2B20-4219-8B87-7F09101B7002Q60950220-B9076DD0-9BEA-413C-93A7-F6069150E728Q64927243-ABA97823-8661-4F46-966A-E090E691B6EAQ68642157-7E919E87-FAFF-42CC-AEC0-E63676F0FB55Q73304027-4117AD3F-4DC7-452E-9F19-76CFD36A1468Q83859461-A6FC017A-8D2B-4342-AA21-CF97C78747EEQ84774070-1A8609D0-D627-42F0-BE7F-D49174A6BEE4Q86031999-A62B8EE3-F66C-40BB-844E-09B624670F44Q90597373-DD9F381E-B957-48B0-BD9F-8AE7EEBC337FQ91393043-4B50EA3B-BA24-41BD-A10A-801112A412F5Q91669644-A4E9DED0-ABC2-4F99-B17D-127C86561F50Q93925994-105429F4-FD5A-44ED-A7F6-E46323EAAEA3
P50
description
researcher ORCID ID = 0000-0002-7823-1904
@en
wetenschapper
@nl
name
Juan J Torrado
@ast
Juan J Torrado
@en
Juan J Torrado
@nl
type
label
Juan J Torrado
@ast
Juan J Torrado
@en
Juan J Torrado
@nl
prefLabel
Juan J Torrado
@ast
Juan J Torrado
@en
Juan J Torrado
@nl
P106
P21
P31
P496
0000-0002-7823-1904